Hansen Medical (NSDQ:HNSN) said today it filed a 510(k) application with the FDA for an expanded neurological indication for its Magellan robotic surgical system.
If the Mountain View, Calif.-based company wins approval, the Magellan system will be fully indicated for applications in peripheral vascular and neurological procedures.
“Our experience in performing robotically assisted carotid stent procedures has shown that there could be important advantages for neuro applications including many of the benefits we have seen in other applications, like embolization and other endovascular therapies,” Dr. Barry Katzen of the Miami Cardiac & Vascular Institute said in a press release.
“We anticipate that an added neurological indication would allow us to bring the benefits of robotics to a new specialty of physicians who could, in turn, offer robotic solutions to a new patient population. We are excited by the potential to expand the procedure base in which robotics can play a role,” CEO Cary Vance said in a prepared statement.
Last week, Auris Surgical Robotics mixed up the robotic surgery game, saying it signed a deal to buy Hansen Medical for approximately $80 million.
Through the merger agreement, Auris will pay $4 per share in cash, which the company says is approximately 39.9% over the closing sale price of the common stock of Hansen Medical as reported yesterday.
Moll founded Hansen Medical in 2002 with an eye toward the intravascular space. Moll, a serial entrepreneur, also co-founded Mako Surgical, acquired in 2013 by Stryker Corp. and Restoration Robotics and its Artas hair restoration platform.
